# Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

> **NCT02106546** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 970 (actual)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Veliparib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo to veliparib

## Key facts

- **NCT ID:** NCT02106546
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-10
- **Primary completion:** 2017-01-03
- **Final completion:** 2019-11-20
- **Target enrollment:** 970 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106546, "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02106546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*